The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding promises. It's a good economic investment, says the Fund's Peter Sands, into a ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration approval, with a decision expected in mid-June, Gilead Sciences Inc. announced ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, ...